NanoViricides Provides an Update on Its Clinical Program ...

NanoViricides, Inc. updates on NV-387, a broad-spectrum antiviral drug mimicking host cells to disable viruses. Demonstrated effectiveness in animal trials against Influenza, COVID, RSV, and orthopoxviruses. Plans Phase II trials for human effectiveness, aiming for regulatory approval and market entry. Exploring collaborations to accelerate development.